X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cipla with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ADCOCK INGRAM (S. Africa) - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   ADCOCK INGRAM
EQUITY SHARE DATA
    CIPLA
Mar-18
ADCOCK INGRAM
Jun-14
CIPLA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs663349-   
Low Rs479252-   
Sales per share (Unadj.) Rs189.0103.7-  
Earnings per share (Unadj.) Rs17.6-26.1-  
Cash flow per share (Unadj.) Rs34.0-21.7-  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs176.781.4-  
Shares outstanding (eoy) m805.12168.78-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.02.9 104.4%   
Avg P/E ratio x32.5-11.5 -282.6%  
P/CF ratio (eoy) x16.8-13.9 -121.1%  
Price / Book Value ratio x3.23.7 87.6%  
Dividend payout %17.10-   
Avg Mkt Cap Rs m459,72450,658 907.5%   
No. of employees `00023.64.3 550.0%   
Total wages/salary Rs m26,9013,179 846.1%   
Avg. sales/employee Rs Th6,446.14,078.4 158.1%   
Avg. wages/employee Rs Th1,139.4740.6 153.8%   
Avg. net profit/employee Rs Th600.0-1,027.7 -58.4%   
INCOME DATA
Net Sales Rs m152,19317,508 869.3%  
Other income Rs m3,577123 2,917.0%   
Total revenues Rs m155,76917,631 883.5%   
Gross profit Rs m28,264-3,034 -931.5%  
Depreciation Rs m13,228756 1,750.6%   
Interest Rs m1,142474 240.9%   
Profit before tax Rs m17,470-4,141 -421.8%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,501259 966.5%   
Profit after tax Rs m14,166-4,412 -321.1%  
Gross profit margin %18.6-17.3 -107.2%  
Effective tax rate %14.3-6.2 -229.1%   
Net profit margin %9.3-25.2 -36.9%  
BALANCE SHEET DATA
Current assets Rs m108,14112,823 843.3%   
Current liabilities Rs m38,3227,215 531.1%   
Net working cap to sales %45.932.0 143.2%  
Current ratio x2.81.8 158.8%  
Inventory Days Days97111 87.5%  
Debtors Days Days74124 60.0%  
Net fixed assets Rs m109,4117,475 1,463.7%   
Share capital Rs m1,61081 1,980.8%   
"Free" reserves Rs m140,6820-   
Net worth Rs m142,29213,742 1,035.4%   
Long term debt Rs m36,6214,829 758.3%   
Total assets Rs m228,60625,960 880.6%  
Interest coverage x16.3-7.7 -210.7%   
Debt to equity ratio x0.30.4 73.2%  
Sales to assets ratio x0.70.7 98.7%   
Return on assets %6.7-15.2 -44.1%  
Return on equity %10.0-32.1 -31.0%  
Return on capital %10.0-19.8 -50.3%  
Exports to sales %32.80-   
Imports to sales %00-   
Net fx Rs m30,6580-   
CASH FLOW
From Operations Rs m14,6281,494 978.8%  
From Investments Rs m-8,540-459 1,861.1%  
From Financial Activity Rs m-3,8554,383 -88.0%  
Net Cashflow Rs m2,4315,418 44.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.81 Rs / ZAR

Compare CIPLA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare CIPLA With: J.B.CHEMICALS  ELDER PHARMA  ALEMBIC LTD  GSK PHARMA  NOVARTIS  



Today's Market

Indian Indices Trade Flat; Energy and Power Stocks Witness Buying(12:30 pm)

Share markets in India are presently trading near the dotted line. Sectoral indices are trading on a mixed note with stocks in the energy sector and power sector.

Related Views On News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8% (Quarterly Result Update)

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 21, 2018 03:33 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS